US Pre-Market SEC Filings Roundup — April 06, 2026

06-04-2026

The Charles Schwab Corporation issued Definitive Additional Proxy Materials (DEFA14A) for its virtual Annual Meeting of Stockholders on May 21, 2026, at 11:00 AM Central Time. Key proposals include election of directors Marianne C. Brown, Frank C. Herringer, Richard A. Wurster, and Carolyn Schwab-Pomerantz for three-year terms; ratification of Deloitte & Touche LLP as independent auditors for 2026; advisory approval of named executive officer compensation; and approval of amendments to declassify the Board of Directors. The Board recommends voting FOR all proposals 1 through 4.

• ·Paper copy requests must be made by May 11, 2026
• ·Virtual meeting access and voting at www.proxydocs.com/SCHW
• ·Proxy materials available online; no paper delivery unless requested

06-04-2026

Mid-America Apartment Communities, Inc. filed Definitive Additional Proxy Materials (DEFA14A) on April 06, 2026, as an amendment to prior proxy statements pursuant to Section 14(a) of the Securities Exchange Act of 1934. The filing indicates no fee was required and was submitted by the registrant. No specific proposals, voting details, or substantive content is included in the provided header.

• ·Filing Type: DEFA14A (Schedule 14A Information Proxy Statement Amendment)
• ·Filed by the Registrant (☒)

06-04-2026

Profusa, Inc. entered into a non-binding Letter of Intent (LOI), dated March 31, 2026, as amended April 4, 2026, to acquire Bio Insights LLC's PanOmics assets for $30 million in stock, including 460,000 common shares at closing (capped at 19.99% of outstanding shares) and preferred stock convertible into 59,540,000 common shares after one year. The deal includes plans for $10 million in additional equity financing, allocation of up to $2 million for PanOmics validation, 3% net revenue royalties to Bio Insights, and board nomination rights, but remains subject to due diligence, definitive agreements by May 1, 2026, and shareholder approval before June 30, 2026.

• ·LOI terminates automatically on May 1, 2026, unless extended or definitive agreements executed.
• ·Exclusivity period prevents Bio Insights from engaging with other parties on similar transactions.
• ·Lock-up on conversion shares for 7 years with annual 1/7th releases and tax liability carve-out.
• ·Samples: Cohort 1 ([***] samples) within 5 business days post-closing; Cohort 2 ([***] samples) within 30 days post-MTA.

06-04-2026

CenterPoint Energy, Inc. issued definitive additional proxy materials on April 6, 2026, recommending shareholders vote FOR Proposal 4 at the April 16, 2026 Annual Meeting to amend its Charter with a limited officer exculpation provision for breach of duty of care, aligning with recent Texas law amendments and existing director protections. The Board unanimously supports this narrowly tailored update, which excludes derivative claims and aims to reduce litigation/insurance costs, ensure consistent treatment between directors and officers, and aid in attracting/retaining talent, as over 650 Delaware public companies have adopted similar provisions since August 2022.

• ·Original proxy statement filed March 4, 2026.
• ·Proxy solicitor contact: Okapi Partners, LLC, toll-free (877) 796-5274 or info@okapipartners.com.
• ·Exculpation excludes: duty of loyalty breaches, bad faith, intentional misconduct, knowing law violations, improper benefits, or statutory liabilities.

06-04-2026

Genworth Financial, Inc. (GNW) has filed definitive additional proxy materials (DEFA14A) for its 2026 Annual Meeting on May 20, 2026, at 9:00 a.m. ET virtually. Shareholders are to vote on electing ten director nominees, advisory approval of named executive officer compensation, approval of the 2026 Associate Stock Purchase Plan, and ratification of KPMG LLP as the independent auditor for 2026, with the Board recommending 'FOR' all items. No financial performance metrics or period comparisons are provided in the filing.

• ·Vote deadline: May 19, 2026 11:59 PM ET (May 17 for Plan shares, May 18 for Canadian Plan shares)
• ·Request proxy materials by May 6, 2026 via www.ProxyVote.com, 1-800-579-1639, or sendmaterial@proxyvote.com
• ·Virtual meeting URL: www.virtualshareholdermeeting.com/GNW2026
• ·This is the Board's WHITE proxy card

06-04-2026

Westlake Corporation entered into a new Credit Agreement dated April 2, 2026, with JPMorgan Chase Bank, N.A. as Administrative Agent and a syndicate of lenders including joint bookrunners BofA Securities, Inc., Wells Fargo Securities, LLC, and Deutsche Bank Securities Inc. The facility supports revolving borrowings and letters of credit in Agreed Currencies, with an Alternate Currency Sublimit of $1.5 billion and pricing at Level III based on public debt ratings (equivalent to BBB/Baa2/BBB). No performance declines or comparisons are disclosed in the filing.

• ·Filing date: April 6, 2026
• ·Current Applicable Rate at Pricing Level III: Term Benchmark Loans 125.0 bps, RFR Loans 125.0 bps, ABR Loans 25.0 bps, Undrawn Commitment Fee 12.5 bps
• ·Alternate Currencies include Euros and Pounds Sterling
• ·Agreed Currencies: U.S. Dollars and Alternate Currencies

06-04-2026

Baker Hughes Company filed a supplement to its March 30, 2026 Proxy Statement on April 6, 2026, specifically revising the voting standards description on page 88 for the 2026 Annual Meeting of Shareholders on May 19, 2026. The update details quorum requirements (majority of Common Stock present or by proxy) and majority-of-votes-cast standards for director elections, advisory vote on executive compensation, ratification of KPMG LLP as auditor for fiscal year 2026, approval of the 2026 Long-Term Incentive Plan, and the Second Amended and Restated Employee Stock Purchase Plan. The supplement does not alter any proposals, board recommendations, or require action from shareholders who have already voted unless they choose to change their vote.

• ·Abstentions and broker non-votes have no effect on director elections or the specified proposal approvals.
• ·Capitalized terms in the supplement refer to definitions in the original Proxy Statement.

06-04-2026

Encore Medical, Inc. filed Amendment No. 4 to its Form S-1 registration statement (No. 333-290244) on April 3, 2026, as an exhibit-only filing to add Exhibit 4.3 (Form of 2021–2022 Investor’s Warrant) and Exhibit 107 (Filing Fee Table), with no changes to the prospectus or other sections. The company is classified as an emerging growth company, smaller reporting company, and non-accelerated filer. This amendment supports the ongoing IPO process with commencement of proposed sale to the public as soon as practicable after effectiveness.

• ·Incorporated in Minnesota; I.R.S. Employer Identification Number: 82-2906303.
• ·Principal executive offices: 2975 Lone Oak Drive, Suite 140, Eagan, MN 55121.
• ·Primary Standard Industrial Classification Code Number: 3841.
• ·Agent for service: Joseph A. Marino at company address.

06-04-2026

Innovative Food Holdings Inc. (IVFH) filed a DEFA14A additional proxy statement ahead of its stockholder meeting on May 19, 2026, at 10:00 AM ET in Broadview, IL. Shareholders will vote on electing five directors (James C. Pappas, Mark Schmulen, Denver J. Smith, Gary Schubert, Loukas D. Kozonis), ratifying CBIZ CPAs P.C. as independent auditors for the fiscal year, and approving executive compensation on a non-binding advisory basis. Materials can be requested by May 5, 2026, via ProxyVote.com, phone, or email.

• ·Meeting address: 2528 S 27th Ave, Broadview, IL 60155
• ·Request proxy materials by May 5, 2026
• ·Voting options: www.ProxyVote.com, 1-800-579-1639, or sendmaterial@proxyvote.com (include control number)

06-04-2026

Agilent Technologies, Inc. filed an 8-K/A to correct the header of its prior 8-K, disclosing that Bret DiMarco, Senior Vice President, Chief Legal Officer and Secretary, entered a Transition Agreement on March 31, 2026, to resign from his roles by the earlier of a new Chief Legal Officer start date or September 30, 2026, and serve as Special Advisor until December 1, 2026. As Special Advisor, he will receive an annualized base salary of $350,000, retain health benefits and equity vesting, but forgo new equity grants and the 2026 fiscal year bonus. A lump sum payment equal to one times his current base salary plus target bonus, minus advisor salary paid, will follow his service upon execution of a supplemental release.

• ·Transition Agreement filed as Exhibit 10.1
• ·Original 8-K filed March 31, 2026, with incorrect Item 5.01 header
• ·8-K/A filed April 6, 2026; signed April 3, 2026

06-04-2026

PodcastOne, Inc. filed an S-3 shelf registration statement on April 3, 2026, enabling offerings of up to $150 million in common stock, preferred stock, debt securities, and/or warrants from time to time. The prospectus emphasizes substantial risks, including significant ongoing operating and net losses, substantial doubt about the company's ability to continue as a going concern, ineffective disclosure controls and internal controls over financial reporting for the fiscal year ended March 31, 2025, and heavy reliance on LiveOne for operations and debt obligations. No current financial performance data or period comparisons are provided.

• ·Fiscal year end: March 31
• ·Former name: Courtside Group, Inc. (name change effective July 29, 2022)
• ·Business address: 345 North Maple Drive, Suite 295, Beverly Hills, CA 90210
• ·LiveOne owns a substantial majority of PodcastOne's common stock and voting power
• ·Company is a 'controlled company' under Nasdaq standards due to LiveOne's ownership

06-04-2026

Mountain Crest Acquisition 6 Corp., a blank check company (SPAC), filed an S-1 registration statement on April 6, 2026, for an IPO with units to list on Nasdaq under symbols MCAH and MCAHR upon separate trading. The filing extensively discloses risks of pursuing a business combination with PRC-based targets, including VIE structure uncertainties, CSRC filing requirements, cybersecurity reviews, and potential government interventions that could render securities worthless. No specific business combination target or financial performance data is provided, emphasizing pre-operational status with no subsidiaries, dividends, or cash transfers to date.

• ·CSRC Trial Measures promulgated February 17, 2023, effective March 31, 2023.
• ·New Measures for Cybersecurity Review effective February 15, 2022.
• ·CSRC filing exemptions for prior listings completed before September 30, 2023.
• ·Risk factors detailed starting on page 81, including VIE enforceability and currency controls on page 98.
• ·No permissions required from PRC authorities like CSRC or Cyberspace Administration of China for this offering as of prospectus date.

06-04-2026

STRATEGIC ACQUISITIONS INC reported a reduced net loss of $40,223 for the year ended December 31, 2025, compared to $123,716 in 2024 (restated), driven by lower operating expenses ($40,223 vs. $144,822) and elimination of interest expense. However, revenue dropped to $0 from $43,671, primarily due to no interest income from Bitcoin-collateralized loans after full principal repayment in 2024, while cash plummeted 98% to $508 and total assets declined 78% to $5,388 amid reduced liabilities to $13,319.

• ·Basic and diluted net loss per share improved to $(0.01) from $(0.02).
• ·Net cash used in operating activities decreased to $30,473 from $110,124.
• ·Stockholders’ equity deficit narrowed to $(7,931) from $(81,029).
• ·Non-cash capital contribution of $11,000 for expenses paid on behalf of the company in 2025.
• ·No loans receivable or digital asset collateral remaining at end of 2025.

06-04-2026

Cal Redwood Acquisition Corp., a SPAC targeting TMT businesses, filed an amended 10-K for the period from inception (January 7, 2025) through December 31, 2025, highlighting management expertise led by Mr. Ranadivé, who grew TIBCO to over $1B in annual revenue and $4.3B equity value via 30 M&A deals before its 2014 sale. The filing details redemption policies for its initial business combination, with public shares redeemable at approximately $10.00 per share from the trust account, and full redemption by the May 27, 2027 deadline if no deal is completed; it also notes risks such as insufficient working capital potentially requiring sponsor loans and debt-related constraints post-combination.

• ·Financial statements cover period from January 7, 2025 (inception) through December 31, 2025.
• ·Initial business combination must be completed by May 27, 2027, or public shares will be redeemed.
• ·Sponsor or affiliates may purchase public shares at no higher than redemption price, with no impact to remaining shareholders.

06-04-2026

On April 3, 2026, Donald A. Moul, President and Chief Executive Officer of Tennessee Valley Authority (TVA), notified the company and its Board of Directors of his intention to retire effective July 1, 2026. This announcement was filed in an 8-K on April 6, 2026, under Item 5.02. No successor has been named in the filing.

• ·Filing signed by Thomas C. Rice on April 3, 2026.

06-04-2026

Aperture AC, a Cayman Islands blank check company, filed Amendment No. 2 to its S-1 registration statement for an initial public offering of 9,000,000 units at $10.00 each, aiming to raise $90,000,000, with an underwriters' over-allotment option for up to 1,350,000 additional units. The sponsor, Aperture Sponsor LLC, holds 3,828,082 Class B founder shares (purchased for $25,000) designed to represent 27% ownership post-IPO (subject to potential surrender of up to 499,315 shares), and has committed to a simultaneous private placement of 267,500 units for $2,675,000. Public shareholders will have redemption rights upon a business combination, but face immediate dilution from low-cost founder shares and potential anti-dilution adjustments.

• ·Registrant is a non-accelerated filer, smaller reporting company, and emerging growth company.
• ·Principal executive offices: 835 Wilshire Blvd. 5th Floor, Los Angeles, CA 90017; prior address referenced as 28 N 3rd St., Apt A404, Alhambra, CA 91801.
• ·SEC file number: 333-291583; fiscal year end: December 31.
• ·15% aggregate redemption limit for shareholders acting in concert if shareholder vote on business combination.
• ·Founder shares convertible to Class A on 1:1 basis (subject to anti-dilution adjustments maintaining ~27% ownership).

06-04-2026

Oxbridge Re Holdings Limited filed a 10-K/A amendment on April 6, 2026, disclosing grants of restricted shares to NEOs Mr. Madhu and Mr. Timothy in fiscal year 2025 under the 2021 Omnibus Incentive Plan, subject to vesting over three quarters based on continued employment. Equity compensation plans approved by shareholders show 451,250 securities to be issued upon exercise at a weighted average price of $5.42, with 1,569,514 securities remaining available for future issuance. The filing includes an extensive list of exhibits referencing various incentive plans, employment agreements, and other corporate documents, many incorporated by reference from prior 8-K filings.

• ·Restricted shares granted to NEOs carry shareholder rights including dividends and were valued using FASB ASC Topic 718 grant date fair value.
• ·Exhibits include amended employment agreements dated August 28, 2025 for Jay Madhu and Wrendom Timothy, and corporate action agreements for Sanjay Madhu and Wrendom Timothy.
• ·Equity Distribution Agreement dated July 9, 2025 with Maxim Group LLC.

06-04-2026

Shareholders of XAI Octagon Floating Rate & Alternative Income Trust (XFLT) and XAI Madison Equity Premium Income Fund (MCN) are solicited to vote at the joint annual meeting on May 7, 2026, to elect Scott Craven Jones and William T. Meyers as Class III Trustees for each fund, serving until the 2029 annual meeting. The Board of Trustees unanimously recommends voting 'FOR' the nominees, with the record date set as March 27, 2026. As of the record date, XFLT had 15,230,918 common shares and 7,300,000 preferred shares outstanding, while MCN had 21,116,722 common shares outstanding.

• ·Meeting location: 321 N. Clark Street, Suite 2430, Chicago, IL 60606 at 9:00 a.m. Central time.
• ·Vote required: Affirmative vote of a majority of shares present in person or by proxy at meeting with quorum.
• ·Proxy solicitation allows voting by mail, telephone, or internet; in-person voting requires ID and proof of ownership.

06-04-2026

XAI Octagon Floating Rate & Alternative Income Trust (XFLT) and XAI Madison Equity Premium Income Fund (MCN) have issued a joint proxy statement for their annual meeting on May 7, 2026, to elect Scott Craven Jones and William T. Meyers as Class III Trustees for each fund, serving until the 2029 annual meeting. The Board of Trustees unanimously recommends voting FOR the nominees. As of the record date of March 27, 2026, XFLT had 15,230,918 common shares and 7,300,000 preferred shares outstanding, while MCN had 21,116,722 common shares outstanding.

• ·Annual Meeting location: 321 N. Clark Street, Suite 2430, Chicago, IL 60606 at 9:00 a.m. Central time
• ·Record date: close of business on March 27, 2026
• ·Shareholder contact: (888) 903-3358
• ·XFLT shares: Common par value $0.01 per share; Preferred: Series A Mandatory Redeemable Preferred Shares
• ·MCN shares: Common par value $0.01 per share; No preferred shares
• ·Vote required: Majority of shares present in person or by proxy at meeting with quorum

06-04-2026

Ooma, Inc. filed an S-3 shelf registration statement on April 3, 2026, enabling the future issuance of unspecified securities for general corporate purposes, with net proceeds to be used at the company's discretion. The company is authorized to issue up to 100,000,000 shares of common stock (par value $0.0001 per share) and 10,000,000 shares of preferred stock (par value $0.0001 per share), with no preferred shares currently outstanding. The filing includes standard forward-looking statements, risk disclosures, and anti-takeover provisions such as a classified board and Delaware Section 203 protections.

• ·No shares of preferred stock are currently outstanding, and no current plans to issue any.
• ·Stockholders may remove directors only for cause; board vacancies filled only by the board.
• ·Special meetings of stockholders callable only by majority of board, chairman, CEO, or president.
• ·Subject to Section 203 of Delaware General Corporation Law, restricting business combinations with interested stockholders for three years.

06-04-2026

Laird Superfood, Inc. filed an 8-K/A providing audited historical consolidated financial statements of acquired Global Superfoods Corp. (successor to Navitas LLC) as part of acquisition completion. For the year ended December 31, 2025, the successor reported net sales of $45,284,000 (up ~24% from combined 2024 periods of $36,406,700), gross profit of $14,392,200, and net income of $1,583,800, reflecting a turnaround from net losses of $729,500 in 2024 periods. However, cash declined to $158,600 from $314,700 year-over-year, line of credit increased to $2,000,000, and prior predecessor members' deficit stood at $(40,876,700) with going concern doubts alleviated by the acquisition.

• ·Allowance for credit losses: $4,300 (Dec 31, 2025) vs $5,600 (Dec 31, 2024)
• ·Line of credit: $2,000,000 (Dec 31, 2025) vs $200,000 (Dec 31, 2024)
• ·Predecessor members’ deficit as of May 23, 2024: $(40,876,700)
• ·Going concern doubt alleviated by acquisition as per Note 16
• ·Audited by Baker Tilly US, LLP

06-04-2026

The Honest Company, Inc. entered into the First Amendment to its Credit Agreement and Pledge and Security Agreement, both originally dated January 25, 2023, as of March 31, 2026, subject to conditions precedent including executed documents, legal opinions, secretary certificates, and representations of no Default or Event of Default. The amendments update specific sections, schedules, exhibits, and render Section 2 of the Fee Letter inapplicable, while ratifying the existing loan documents without waiving any rights or remedies. No quantitative changes to facility terms are disclosed in the filing.

• ·Amendment filed as 8-K on April 06, 2026 (Items 1.01, 1.02, 2.03, 9.01).
• ·Governed by laws of the State of California.
• ·Executed in counterparts with electronic signatures permitted.

06-04-2026

JPMorgan Chase & Co.'s 2026 proxy statement highlights record 2025 financial performance, including managed revenue of $185.6 billion, net income of $57.0 billion, ROE of 17%, and ROTCE of 20%, reflecting strong business execution and shareholder value creation. The document details robust board governance, recent committee reassignments, leadership under James Dimon, and support for the Security and Resiliency Initiative, with no material declines or flat metrics reported. The annual shareholder meeting is set for May 19, 2026, virtually at 10:00 a.m. ET.

• ·Annual shareholder meeting on May 19, 2026 at 10:00 a.m. Eastern Time, virtual format.
• ·Board meets at least eight times per year with independent director sessions.
• ·Recent committee changes: Ginni Rometty as Chair of Corporate Governance & Nominating Committee; Alex Gorsky and Michele Buck joined CGNC; Brad Smith and Alicia Boler Davis joined Public Responsibility Committee.

06-04-2026

Greenpro Capital Corp. consummated a Share Exchange Agreement on March 31, 2026, acquiring 1,360 ordinary shares of Forekast Limited (13.6% of its outstanding equity on a fully diluted basis) in exchange for issuing 8,500,000 shares of its common stock to Forekast shareholders. This nearly doubled outstanding shares from 8,625,813 to 17,125,813, significantly diluting existing ownership, with directors and officers' collective stake dropping from 39.67% to 19.98% and principal shareholders now holding 52.88%. The transaction was a minority investment without gaining control of Forekast.

• ·BHL Ltd. received 3,250,000 Company shares for 520 Forekast shares (previously 5.2% Forekast owner).
• ·Moira Venture Limited, Renhari Limited, Joharne Limited, Crescent East Limited, and Stratifi Global Limited each received 1,125,000 Company shares for 180 Forekast shares (previously 1.8% each).
• ·Exchange Shares issued under Rule 506 of Regulation D as restricted securities.

06-04-2026

On April 6, 2026, Playtika Holding Corp. (PLTK) issued a press release announcing that a special committee of its board of directors is conducting a process to review and evaluate potential strategic alternatives to enhance stockholder value. The disclosure is made under Item 7.01 (Regulation FD Disclosure) and includes Exhibit 99.1, which is not deemed 'filed' under Section 18 of the Exchange Act. The filing was signed by Michael Cohen, Chief Legal Officer.

06-04-2026

AirSculpt Technologies reported fourth quarter 2025 revenue of $33.4 million, down 14.6% YoY from $39.2 million, and full year 2025 revenue of $151.8 million, down 15.8% YoY from $180.4 million, driven by case volume declines of 15.0% to 2,604 and 15.6% to 11,852 respectively. While Q4 net loss improved to $1.3 million from $5.0 million YoY, full year net loss widened to $11.7 million from $8.0 million, and Adjusted EBITDA fell to $(0.1) million in Q4 and $12.5 million for the year from $1.9 million and $21.0 million prior year. The company provided 2026 guidance of $151-157 million revenue and $15-17 million Adjusted EBITDA, noted sequential same-store sales improvement turning positive in February 2026, raised $14.8 million via at-the-market offering, and reduced gross debt to $45.0 million.

• ·Q1 2026 revenue guidance: $38.5 to $39.5 million (same-store revenue approximately flat at midpoint)
• ·FY 2026 revenue guidance: $151 to $157 million; Adjusted EBITDA: $15 to $17 million
• ·As of Dec 31, 2025: $5.0 million borrowing capacity under revolving credit facility; in compliance with all debt covenants
• ·Q4 same-center cases: 2,345 (-18.5% YoY); FY same-center cases: 10,670 (-22.1% YoY)
• ·Loss on impairment of long-lived assets FY2025: $4.5 million (Salesforce project and corporate office PPE); Cost related to closing location: $2.2 million

06-04-2026

Biogen Inc. expects approximately $34 million in acquired in-process research and development, upfront and milestone expenses for the first quarter of 2026 on a pre-tax basis, negatively impacting both GAAP and non-GAAP net income per diluted share by about $0.19. These preliminary unaudited results for the quarter ended March 31, 2026, are subject to final financial statement closing procedures and may differ from final figures. The company notes uncertainty in forecasting such expenses due to their unpredictable timing and magnitude.

• ·Expenses include costs from collaboration and license agreements, such as upfront and milestone payments, premiums on equity securities, and asset acquisitions.
• ·Biogen does not forecast such acquired in-process research and development expenses due to uncertainty in future occurrence, magnitude, and timing.

06-04-2026

Cycurion, Inc. filed an 8-K on April 6, 2026, disclosing the issuance of press releases on April 1, 2026 (Exhibit 99.1) and April 2, 2026 (Exhibit 99.2) under Item 8.01 Other Events. The filing confirms the company's common stock (CYCU) and redeemable warrants (CYCUW, exercisable at $345.00 per share) are listed on The NASDAQ Stock Market LLC. No financial results, performance metrics, or specific details from the press releases are included in the filing body.

• ·State of incorporation: Delaware
• ·Commission File Number: 001-41214
• ·IRS Employer Identification No.: 86-3720717
• ·Principal executive offices: 1640 Boro Place, Suite 420C, McLean, Virginia 22102
• ·Emerging growth company: Yes

06-04-2026

Inflection Point Acquisition Corp. VI, a blank check company, consummated its IPO on March 30, 2026, issuing 25,300,000 units at $10.00 per unit for gross proceeds of $253,000,000, including 3,300,000 units from the underwriters' over-allotment option. Simultaneously, it completed a private placement of 7,400,000 warrants at $1.00 each to its sponsor and Cantor Fitzgerald & Co., generating $7,400,000. A total of $253,000,000 was placed in trust, with the balance sheet reflecting total assets of $255,206,776 but a shareholders' deficit of $10,024,533 due to offering costs and accumulated deficit.

• ·Promissory note – related party: $36,858
• ·Accrued offering costs: $103,232
• ·Transaction costs breakdown: $4,400,000 cash underwriting fee + $12,045,000 deferred + $832,094 other
• ·Company inception: September 12, 2025
• ·Fiscal year end: December 31
• ·Business Combination requirement: target fair market value at least 80% of trust net assets
• ·IPO registration statement effective: March 26, 2026

06-04-2026

Madison Air Solutions Corp's S-1/A filing highlights significant risks ahead of its IPO, including material weaknesses in internal controls, limited public company experience, tax uncertainties, and substantial indebtedness totaling $3,977.7 million as of December 31, 2025. While cash flows from operating activities increased sharply to $480.0 million in FY2025 from $220.4 million in FY2024 (+118% YoY), debt service cash outflows rose to $549.2 million (68% of operating cash flows before interest), up from $318.9 million in FY2024. Post-offering, expected annual debt service is projected to decline to $208.9 million, all interest-related.

• ·Sixth Amendment to Credit Agreement entered March 20, 2026, providing for 2026 Incremental Revolving Facility, effective post-offering.
• ·Tax Matters Agreement requires indemnification of Madison Industries International for certain tax liabilities from Organizational Transactions.
• ·Transition Services Agreement with Madison Industries International for tax compliance and other services post-separation.

06-04-2026

Clear Channel Outdoor Holdings, Inc. commenced a consent solicitation on April 6, 2026, for its outstanding senior secured notes totaling $865M (7.875% due 2030), $1,150M (7.125% due 2031), and $900M (7.500% due 2033) to amend indenture provisions, including the 'Change of Control' definition, facilitating its pending merger without triggering a repurchase offer. The merger, under the February 9, 2026 Agreement with Madison Parent Inc. and Madison Merger Sub Inc., will make the company a wholly-owned subsidiary of Parent, backed by Mubadala Capital and TWG Global; however, the merger is not conditioned on consent success and carries risks including potential delays, termination fees, litigation, and adverse effects on stock price and operations.

• ·Merger would otherwise require Change of Control Offer to repurchase notes at 101% of principal plus accrued interest
• ·Special Meeting of stockholders to be announced promptly for Merger approval; definitive proxy statement to be filed with SEC
• ·Merger obligations not conditioned on Consent Solicitation success

06-04-2026

Atlas Energy Solutions Inc. (NYSE: AESI) announced a private placement offering of $300 million aggregate principal amount of Convertible Senior Notes due 2031 to qualified institutional buyers under Rule 144A, with an option for initial purchasers to buy up to an additional $45 million. Net proceeds will partially fund capped call transactions, repay approximately $66 million in advances under agreements with Stonebriar Commercial Finance LLC (including a $5 million termination fee), repay $75 million under its 2023 ABL Credit Facility, and support general corporate purposes such as purchasing power generation equipment under the Global Framework Agreement with Caterpillar Inc. The notes are senior unsecured, mature on April 15, 2031, accrue semi-annual interest, and include conversion, redemption after April 20, 2029, and fundamental change repurchase rights.

• ·Notes offered pursuant to Rule 144A, unregistered under Securities Act.
• ·Settlement of conversions in cash, Common Stock ($0.01 par value), or combination.
• ·Redemption possible on/after April 20, 2029, if stock price >=130% of conversion price.
• ·Option counterparties expected to hedge via stock purchases/derivatives, potentially impacting stock price.

06-04-2026

INOVIO Pharmaceuticals, Inc. (Nasdaq: INO) announced a proposed underwritten public offering of shares of its common stock and accompanying Series A and Series B warrants (or pre-funded warrants in lieu thereof), all to be sold by the company. Piper Sandler is acting as sole manager, with INOVIO intending to grant a 30-day underwriter option to purchase up to 15% additional securities under the same terms. The offering is subject to market conditions, with no assurance of completion, size, or terms, and will be made via a prospectus supplement to a previously effective shelf registration.

• ·Shelf registration statement filed with SEC on November 9, 2023, and declared effective on January 31, 2024.
• ·Prospectus available via Piper Sandler at (800) 747-3924 or prospectus@psc.com.
• ·INOVIO focused on DNA medicines for HPV-related diseases, cancer, and infectious diseases.

06-04-2026

Legence Corp. filed an S-1 registration statement on April 6, 2026, presenting unaudited pro forma condensed combined financial information reflecting its acquisition of The Bowers Group, Inc. (Bowers) completed on January 2, 2026, for total estimated consideration of $426.6 million, including $283.1 million cash, 2,551,672 shares of Class A common stock valued at $98.6 million, and $44.9 million deferred consideration. Pro forma combined revenue for the year ended December 31, 2025, reaches $3,449,898 thousand, combining Legence's historical $2,550,491 thousand with Bowers' $902,357 thousand after adjustments, while pro forma total assets stand at $3,265,176 thousand as of December 31, 2025. The acquisition was financed via a $200.0 million incremental term loan, cash on hand, and revolver borrowings, following Legence's prior IPO in September 2025 which raised net proceeds of $780.2 million.

• ·Pro forma combined total liabilities as of December 31, 2025: $2,390,907 thousand.
• ·Pro forma combined total equity as of December 31, 2025: $874,269 thousand.
• ·IPO commenced trading on Nasdaq Global Select Market on September 12, 2025, and closed on September 15, 2025.
• ·Acquisition shares subject to lock-up through March 10, 2026.

06-04-2026

Neurocrine Biosciences (NBIX) has agreed to acquire Soleno Therapeutics (SLNO) for $53.00 per share in cash, representing a total equity value of $2.9 billion and premiums of 34% to the April 2, 2026 closing price and 51% to the 30-day VWAP. The deal adds VYKAT XR (diazoxide choline), which generated $190 million in 2025 revenue ($92 million in Q4), to Neurocrine's portfolio of first-in-class therapies including INGREZZA ($2.51 billion in 2025 revenue) and CRENESSITY ($301 million in 2025 revenue), strengthening its endocrinology and rare disease presence with IP extending into the mid-2040s. The transaction, funded by cash and modest debt without a financing condition, is expected to close within 90 days subject to regulatory approvals and customary conditions.

• ·PWS occurs in one in every 15,000 live births per Prader-Willi Syndrome Association USA.
• ·VYKAT XR approved by FDA in March 2025; CRENESSITY approved in December 2024.
• ·Neurocrine to host conference call at 8:00 AM ET on April 6, 2026.
• ·Advisors: Goldman Sachs & Co. LLC (financial, Neurocrine), Cooley LLP (legal, Neurocrine), Centerview Partners LLC and Guggenheim Securities, LLC (financial, Soleno), Wilson Sonsini Goodrich & Rosati (legal, Soleno).

06-04-2026

PMGC Holdings Inc.'s newly formed wholly-owned subsidiary, NorthStrive Defense Tech LLC, entered into an exclusive option agreement to license U.S. Patent No. 12,291,334 for a next-generation multi-domain drone system enabling air-water payload transport with buoyancy-assisted efficiency. The technology targets defense applications such as littoral logistics, autonomous resupply, and sensor deployment in complex environments. While the company plans to develop a commercialization strategy and seek financing during the option period, it notes no guarantees of successful licensing, development, or commercialization.

• ·Option provides exclusive rights in the aerospace and defense technologies field to negotiate a definitive license agreement upon exercise.
• ·Technology features trajectory optimization and dynamic control for obstacle avoidance in underwater terrain.
• ·Company is an emerging growth company; common stock trades as ELAB on Nasdaq.

06-04-2026

Anterix Inc.'s wholly-owned subsidiary, PDV Spectrum Holding Company, LLC, entered into a spectrum license sale agreement with NorthWestern Energy on March 31, 2026, selling 900 MHz broadband licenses covering portions of Montana, South Dakota, and Wyoming. The licenses are in a 6 MHz broadband configuration for nine counties and a 10 MHz configuration for the remaining counties, following FCC issuance of transferable broadband licenses. The company issued a press release and fact sheet, filed as Exhibits 99.1 and 99.2.

• ·FCC issuance of broadband licenses transferable from Anterix to NWE
• ·Filing date: April 6, 2026; Earliest event date: March 31, 2026

06-04-2026

Neurocrine Biosciences has entered a definitive agreement to acquire Soleno Therapeutics for $53.00 per share in cash, representing a total equity value of $2.9 billion, a 34% premium to Soleno's April 2, 2026 closing price and 51% to its 30-day VWAP. The deal adds VYKAT XR, which generated $190 million in 2025 revenue including $92 million in Q4, to Neurocrine's portfolio alongside INGREZZA ($2.51 billion in 2025 revenue) and CRENESSITY ($301 million in 2025 revenue), supported by IP extending into the mid-2040s. The transaction is expected to close within 90 days, subject to customary conditions including regulatory approvals.

• ·VYKAT XR FDA approved March 2025, launched Q2 2025; CRENESSITY approved December 2024
• ·Transaction funded by cash on hand and modest pre-payable debt; not subject to financing condition
• ·Neurocrine conference call at 8:00 AM ET on April 6, 2026
• ·VYKAT XR IP estate expected to extend into mid-2040s